Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies

Ruth M Pfeiffer, Yikyung Park, Aimée R Kreimer, James V Lacey Jr, David Pee, Robert T Greenlee, Saundra S Buys, Albert Hollenbeck, Bernard Rosner, Mitchell H Gail, Patricia Hartge, Ruth M Pfeiffer, Yikyung Park, Aimée R Kreimer, James V Lacey Jr, David Pee, Robert T Greenlee, Saundra S Buys, Albert Hollenbeck, Bernard Rosner, Mitchell H Gail, Patricia Hartge

Abstract

Background: Breast, endometrial, and ovarian cancers share some hormonal and epidemiologic risk factors. While several models predict absolute risk of breast cancer, there are few models for ovarian cancer in the general population, and none for endometrial cancer.

Methods and findings: Using data on white, non-Hispanic women aged 50+ y from two large population-based cohorts (the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial [PLCO] and the National Institutes of Health-AARP Diet and Health Study [NIH-AARP]), we estimated relative and attributable risks and combined them with age-specific US-population incidence and competing mortality rates. All models included parity. The breast cancer model additionally included estrogen and progestin menopausal hormone therapy (MHT) use, other MHT use, age at first live birth, menopausal status, age at menopause, family history of breast or ovarian cancer, benign breast disease/biopsies, alcohol consumption, and body mass index (BMI); the endometrial model included menopausal status, age at menopause, BMI, smoking, oral contraceptive use, MHT use, and an interaction term between BMI and MHT use; the ovarian model included oral contraceptive use, MHT use, and family history or breast or ovarian cancer. In independent validation data (Nurses' Health Study cohort) the breast and ovarian cancer models were well calibrated; expected to observed cancer ratios were 1.00 (95% confidence interval [CI]: 0.96-1.04) for breast cancer and 1.08 (95% CI: 0.97-1.19) for ovarian cancer. The number of endometrial cancers was significantly overestimated, expected/observed = 1.20 (95% CI: 1.11-1.29). The areas under the receiver operating characteristic curves (AUCs; discriminatory power) were 0.58 (95% CI: 0.57-0.59), 0.59 (95% CI: 0.56-0.63), and 0.68 (95% CI: 0.66-0.70) for the breast, ovarian, and endometrial models, respectively.

Conclusions: These models predict absolute risks for breast, endometrial, and ovarian cancers from easily obtainable risk factors and may assist in clinical decision-making. Limitations are the modest discriminatory ability of the breast and ovarian models and that these models may not generalize to women of other races. Please see later in the article for the Editors' Summary.

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Claus EB, Risch N, Thompson WD (1993) The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 28: 115–120.
    1. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, et al. (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81: 1879–1886.
    1. Gail MH, Costantino JP, Pee D, Bondy M, Newman L, et al. (2007) Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 99: 1782–1792.
    1. Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23: 1111–1130.
    1. Vachon CM, van Gils CH, Sellers TA, Scott CG, Maloney SD, et al. (2007) Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res 9: 217.
    1. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, et al. (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91: 1541–1548.
    1. Rosner BA, Colditz GA, Webb PM, Hankinson SE (2005) Mathematical models of ovarian cancer incidence. Epidemiology 16: 508–515.
    1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al. (2011) SEER cancer statistics review, 1975–2008. Bethesda (Maryland): National Cancer Institute. Available: . Accessed 24 June 2013.
    1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388.
    1. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295: 2727–2741.
    1. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, et al. (2009) American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27: 3235–3258.
    1. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, et al. (2000) Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 21: 273S–309S.
    1. Schatzkin A, Subar AF, Thompson FE, Harlan LC, Tangrea J, et al. (2001) Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol 154: 1119–1125.
    1. Michaud DS, Midthune D, Hermansen S, Leitzmann M, Harlan L, et al. (2005) Comparison of cancer registry case ascertainment with SEER estimates and self-reporting in a subset of the NIH-AARP Diet and Health Study. J Registry Manag 32: 70–75.
    1. Colditz GA, Hankinson SE (2005) The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 5: 388–396.
    1. Fritz A, Percy C, Jack A, Shanmugaratnam A, Sobin L, et al... (2000) International classification of diseases for oncology, third edition. Geneva: World Health Organization.
    1. Centers for Disease Control and Prevention National Center for Health Statistics (2013) National Health and Nutrition Examination Survey: NHANES 1999–2000. Available: . Accessed 6 July 2013.
    1. Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Data. Available: .
    1. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, et al. (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91: 1829–1846.
    1. Freedman AN, Yu BB, Gail MH, Costantino JP, Graubard BI, et al. (2011) Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 29: 2327–2333.
    1. Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among U.S. adults, 1999–2008. JAMA 303: 235–241.
    1. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, et al. (2013) SEER cancer statistics review, 1975–2010: cancer of the corpus and uterus, NOS (invasive). Bethesda (Maryland): National Cancer Institute. Available: . Accessed 6 July 2013.
    1. Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, et al. (2006) Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 98: 1215–1226.
    1. Barlow WE, White E, Ballard-Barbash R, Vice PM, Titus-Ernstoff L, et al. (2006) Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 98: 1204–1214.
    1. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, et al. (2008) Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 148: 337–347.
    1. Colditz GA, Rosner B (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 152: 950–964.
    1. Petracci E, Decarli A, Schairer C, Pfeiffer RM, Pee D, et al. (2011) Risk factor modification and projections of absolute breast cancer risk. J Natl Cancer Inst 103: 1037–1048.
    1. Gail MH, Pfeiffer RM (2005) On criteria for evaluating models of absolute risk. Biostatistics 6: 227–239.
    1. Wu LC, Graubard BI, Gail MH (2012) Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years. Ann Intern Med 157: 597–598.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren